Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension

NCT00765674 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00765674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00765674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2008
Completion date
August 31, 2009
Enrollment
1,191 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension